COVID-19 Drug Guide India: What's Actually Approved
The COVID-19 drugs actually approved and in clinical use in India — molnupiravir, nirmatrelvir/ritonavir, remdesivir — per CDSCO and AIIMS/ICMR protocol.
This covers which COVID-19 drugs actually hold CDSCO authorisation in India, why authorisation and ICMR protocol inclusion diverge for at least one of them, what AIIMS's own clinical management guidance says, and what that gap means for a hospital pharmacy's stocking decisions.
Which COVID-19 antiviral drugs are authorised in India?
CDSCO granted molnupiravir restricted use authorisation in India on December 28, 2021, and has separately authorised the nirmatrelvir/ritonavir combination (marketed as Paxlovid), both indicated for mild-to-moderate COVID-19 in patients at higher risk of progression to severe disease. Remdesivir, an earlier IV antiviral, holds its own separate CDSCO authorisation predating both oral options.
These three represent the main covid drug india antiviral options with CDSCO authorisation, each targeting the same underlying goal of reducing progression to severe disease in higher-risk patients, though through different mechanisms and administration routes.
Why isn't molnupiravir included in India's national COVID-19 treatment protocol despite CDSCO authorisation?
ICMR has not included molnupiravir in India's national COVID-19 treatment protocol despite the drug holding CDSCO restricted-use authorisation, citing safety concerns that placed it outside the national protocol's recommended treatment pathway. This is a clear, documented case where regulatory authorisation and national clinical-guideline inclusion diverged for the same drug.
This divergence matters directly for a hospital pharmacy: a drug can be legally available and CDSCO-authorised while a hospital's own clinical protocol, aligned with ICMR guidance rather than CDSCO authorisation alone, chooses not to stock or prescribe it as a default option. Formulary decisions should track ICMR's national protocol position specifically, not authorisation status alone. A pharmacy that stocks purely against the CDSCO authorisation list without checking current ICMR protocol status risks holding inventory a hospital's own clinicians won't prescribe as first-line therapy.
What does AIIMS's clinical management guidance for COVID-19 actually recommend?
AIIMS, working with the ICMR COVID-19 Task Force under the Ministry of Health and Family Welfare, has published clinical guidance for management of adult COVID-19 patients, most recently revised in a version dated May 17, 2021 with subsequent amendments. This guidance sits alongside, and in places diverges from, individual drug authorisation decisions made separately by CDSCO.
AIIMS's guidance framework separates patients by disease severity and oxygen saturation thresholds, directing treatment escalation, including antiviral use, oxygen support and other interventions, based on these clinical criteria rather than a uniform treatment path for every diagnosed case. A hospital pharmacy stocking COVID-19 drugs should structure inventory around this severity-tiered approach rather than treating all three antivirals as interchangeable first-line options.
How do the mechanisms of these three COVID-19 drugs differ?
Molnupiravir works by introducing errors into the viral RNA during replication, nirmatrelvir/ritonavir works by inhibiting a viral protease enzyme essential to viral replication (with ritonavir added specifically to boost nirmatrelvir's blood levels through CYP3A4 inhibition), and remdesivir works as a nucleotide analogue that inhibits viral RNA polymerase administered intravenously. These represent three genuinely distinct antiviral mechanisms, not three versions of the same approach.
The ritonavir component in the nirmatrelvir combination carries its own drug interaction profile independent of nirmatrelvir itself, given ritonavir's well-documented CYP3A4 inhibition affecting numerous other medications; a hospital pharmacy dispensing this combination needs interaction screening against a patient's existing medication list specifically because of the ritonavir component. This is the same CYP3A4-inhibition mechanism seen with other ritonavir-boosted drug combinations used outside COVID-19 treatment, which is a useful reference point for a pharmacist already familiar with those interactions.
What does a hospital pharmacy need to track for COVID-19 drug stocking today?
A hospital's COVID-19 drug stocking decision today should track three separate facts for each drug: current CDSCO authorisation status, current inclusion or exclusion in ICMR's national treatment protocol, and current epidemiological relevance given how COVID-19 case patterns and dominant variants have shifted since these authorisations were first granted. All three can change independently of each other over time.
This is not a static list a hospital can set once and leave unreviewed; regulatory and protocol status for COVID-19 drugs specifically has changed multiple times since 2021 and should be reconfirmed against current CDSCO and ICMR sources before any formulary update. A pharmacy committee reviewing this category on a fixed schedule, rather than reactively after a supply gap appears, avoids ending up with either expired stock of a de-prioritised drug or an unexpected shortage of a currently recommended one.
Why does reliable in-house stocking matter for COVID-19 drug access?
A patient prescribed an authorised, protocol-consistent covid drug india antiviral who can't access it inside the hospital because it isn't in stock faces a genuine treatment-window problem, since these antivirals lose effectiveness the later they're started relative to symptom onset.
Sending that prescription to an outside pharmacy for sourcing costs time a patient in the target treatment window doesn't have, on top of the revenue and continuity loss any outside referral represents.
Medyzen's managed hospital pharmacy services are built around exactly this kind of time-sensitive, reliable in-house stocking, and our piece on prescription leakage covers what a prescription walking out the door costs a hospital more broadly, beyond the specific urgency of a time-limited antiviral window. Our pharmacy inventory management guide covers the stock-rotation discipline needed for a drug category whose demand can spike and fall as sharply as COVID-19 caseload does.
Sources
- 1Guidelines on Clinical Management of COVID-19 — AIIMS Covid Information Portal
- 2Clinical Guidance for Management of Adult COVID-19 Patients — AIIMS, ICMR COVID-19 Task Force, MoHFW
- 3Clinical management protocol for COVID-19 — Ministry of Health and Family Welfare, Government of India
- 4Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review — National Institutes of Health, National Library of Medicine
- 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
This article is for informational purposes and is not a substitute for professional medical advice. Regulatory authorisation and national protocol status for COVID-19 drugs change over time; verify current status against CDSCO, ICMR and AIIMS sources before any clinical or stocking decision. Consult the treating physician for any individual patient's treatment.
FAQ
Frequently asked questions
Molnupiravir holds CDSCO restricted-use authorisation in India, but it is not included in ICMR's national COVID-19 treatment protocol due to cited safety concerns. A prescriber's decision to use it should reflect that gap between authorisation and national protocol guidance.
Paxlovid (nirmatrelvir/ritonavir) inhibits a viral protease enzyme and includes ritonavir to boost blood levels, while molnupiravir works by introducing replication errors into viral RNA. Both are oral antivirals authorised for mild-to-moderate COVID-19 in higher-risk patients, but they differ in mechanism and drug interaction profile.
Yes. Ritonavir is a potent CYP3A4 inhibitor and can significantly raise blood levels of numerous other medications metabolised through that pathway, making medication reconciliation essential before dispensing nirmatrelvir/ritonavir to a patient on other chronic medications.
Remdesivir retains its CDSCO authorisation for COVID-19 in India, though current clinical relevance and hospital-specific protocol positioning should be confirmed against current AIIMS and ICMR guidance rather than assumed from earlier pandemic-phase practice.
No. CDSCO authorisation establishes legal availability, not automatic inclusion in a hospital's clinical protocol. A hospital's stocking decision should follow its own clinical protocol, generally aligned with ICMR national guidance, rather than authorisation status alone, as the molnupiravir example demonstrates directly.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.